The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease

Minerva Medica

Volumn 96, Issue 5, 2005, Pages 353-364

  Seibyl, J ^a   Jennings, D ^a   Tabamo, R ^a   Marek, K ^a  

^a INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

Author keywords

Biomarkers; Imaging; Parkinson disease

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; NONSTEROID ANTIINFLAMMATORY AGENT; PRAMIPEXOLE;

BRAIN DEPTH STIMULATION; CELL LOSS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE MARKER; DOPAMINERGIC SYSTEM; EVALUATION; GENE REPLACEMENT THERAPY; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MEDICAL RESEARCH; MONITORING; NERVE CELL; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PATIENT MONITORING; PHENOTYPE; QUANTITATIVE ANALYSIS; REVIEW; VALIDATION PROCESS;

DIAGNOSTIC ERRORS; DISEASE PROGRESSION; EARLY DIAGNOSIS; HUMANS; PARKINSON DISEASE; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 28544434395     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. 123I beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-94.
2. 123I beta-CIT SPECT. J Neural Transm 2000;107:543-52.
3. Brooks DJ. Morphological and functional imaging studies on the diagnosis and progression of Parkinson's disease. J Neurol 2000;247 Suppl 2:II11-8.
4. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-9.
5. Vingerhoets FJ, Snow BJ, Lee CS, Schulzer M, Mak E, Calne DB. Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism. Ann Neurol 1994;36:759-64.
6. Seibyl JP. Imaging studies in movement disorders. Semin Nucl Med 2003;33:105-13.
7. 127I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites. Synapse 2001;39:332-42.
8. 123I] beta-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-94.
9. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998;39:1500-8.
10. Laruelle M, van Dyck C, Abi-Dargham A, Zea-Ponce Y, Zoghbi SS, Charney DS et al. Compartimental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. J Nucl Med 1994;35:743-54.
11. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-9.
12. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
13. Rajput DR. Accuracy of clinical diagnosis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1993;56:938-9.
14. Quinn N. Parkinsonism-recognition and differential diagnosis. BMJ 1995;310:447-52.
15. Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 1996;334:71-6.
16. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002;73:529-34.
17. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28:99-102.
18. Spottke EA, Volkmann J, Lorenz D, Krack P, Smala AM, Sturm V et al. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 2002;249:759-66.
19. 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med 2004;45:393-401.
20. Group PS. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Parkinson Study Group. Neurology 2000;55:1540-7.
21. 123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000;15:503-10.
22. Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T et al. Striatal dopamine transporter binding assessed by [I-123]IPT and single photon emission computed tomography in patients with early Parkinson's disease: implications for a preclinical diagnosis. Arch Neurol 2000;57:205-8.
23. 123I-loflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004;19:1175-82.
24. 123I) beta-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004;61:1224-9.
25. Ceravolo R, Volterrani D, Gambaccini G, Bernardini S, Rossi C, Logi C et al. Presynaptic nigro-striatal function in a group of Alzheimer's disease patients with parkinsonism: evidence from a dopamine transporter imaging study. J Neural Transm 2004;111:1065-73.
26. Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med 1998;39:1879-84.
27. Parkinson Study Group. A Multicenter Assessment Of Dopamine Transporter Imaging With Dopascan™/SPECT In Parkinsonism. Neurology 2000;55:1540-7.
28. 123I]β-CIT and SPECT imaging versus clinical evaluation in parkinsonian syndrome: unmasking an early diagnosis. Arch Neurol 2004;61:1224-9.
29. Reich S, Le Derman M, Griswold M. Errors and delays in diagnosing Parkinson's disease. Ann Neurol 2002;52(3 Suppl):S382.
30. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord 2003;18:1415-23.
31. Seibyl J, Jennings D, Tabamo R, Marek K. Neuroimaging trials of Parkinson's disease progression. J Neurol 2004;251 Suppl 7:vII9-13.
32. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003;302:830-4.
33. 18F]CFT. Ann Neurol 2000;47:804-8.
34. Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brucke T. Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Mov Disord 2003;18:1266-72.
35. Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-82.
36. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002;10:36-43.
37. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-61.
38. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REALPET study. Ann Neurol 2003;54:93-101.
39. Kieburtz K. Designing neuroprotection trials in Parkinson's disease. Ann Neurol 2003;53 Suppl 3:S100-7; discussion S107-9.
40. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-508.
41. 123I]beta-CIT. Mov Disord 1999;14:436-42.
42. Guttman M, Stewart D, Hussey D, Wilson A, Houle S, Kish S. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559-64.
43. 18F]CFT PET study. J Cereb Blood Flow Metab 2000;20:1604-9.
44. Ahlskog JE, Uitti RJ, O'Connor MK, Maraganore DM, Matsumoto JY, Stark KF et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-6.
45. DeKosky S, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 2003;302:830-4.
46. Marek K, Seibyl J, Scanley B, Laruelle M, Abi-Dargham A, Wallace E et al. [I-1231]CIT spect imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-7.
47. Piccini P, Morrish PK, Turjanski N, Sawle GV, Burn DJ, Weeks RA et al. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol 1997;41:222-9.
48. 18F]dopa PET and clinical study. Brain 2002;125(Pt 10):2248-56.
49. Gasser T. Overview of the genetics of parkinsonism. Adv Neurol 2003;91:143-52.
50. Dekker M, Bonifati V, van Swieten J, Leenders N, Galjaard RJ, Snijders P et al. Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov Disord 2003;18:751-7.